NFDI4DS | UHH-SEMS - Publication Details

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

OPENALEX - Publications

Katrin P. Guillen Maihi Fujita Andrew Butterfield Sandra D. Scherer Matthew H. Bailey and 37 more

Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank patient-derived xenografts (PDXs) and matched organoid cultures from represent greatest unmet need: endocrine-resistant, treatment-refractory metastatic breast cancers. leverage PDXs PDX-derived organoids (PDxO) for drug screening is feasible cost-effective with in vivo validation. Moreover, we demonstrate feasibility using these models precision oncology...

10.1038/s43018-022-00337-6 article EN cc-by Nature Cancer 2022-02-24

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

OPENALEX - Publications

Hua Sun Song Cao R. Jay Mashl Chia-Kuei Mo Simone Zaccaria and 95 more

Abstract Development of candidate cancer treatments is a resource-intensive process, with the research community continuing to investigate options beyond static genomic characterization. Toward this goal, we have established landscapes 536 patient-derived xenograft (PDX) models across 25 types, together mutation, copy number, fusion, transcriptomic profiles, and NCI-MATCH arms. Compared human tumors, PDXs typically higher purity fit dynamic driver events molecular properties via multiple...

10.1038/s41467-021-25177-3 article EN cc-by Nature Communications 2021-08-24

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer

OPENALEX - Publications

Sandra D. Scherer Alessandra I. Riggio Fadi Haroun Yoko S. DeRose H. Atakan Ekiz and 7 more

Abstract Background Metastatic breast cancer (MBC) is incurable, with a 5-year survival rate of 28%. In the USA, more than 42,000 patients die from MBC every year. The most common type estrogen receptor-positive (ER+), and ER+ any other subtype. tumors can be successfully treated hormone therapy, but many acquire endocrine resistance, at which point treatment options are limited. There an urgent need for model systems that better represent human in vivo, where metastasize. Patient-derived...

10.1186/s13058-021-01476-x article EN cc-by Breast Cancer Research 2021-10-30

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

OPENALEX - Publications

Jason J. Zoeller Aleksandr Vagodny Veerle W. Daniëls Krishan Taneja Benjamin Y. Tan and 9 more

Abstract Background Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as majority of TNBC express EGFR. The purpose these studies was to evaluate effectiveness two EGFR-targeted antibody-drug conjugates (ADC: ABT-414; ABBV-321) in combination with navitoclax, an antagonist anti-apoptotic BCL-2 and BCL-X L proteins, order assess translational relevance combinations TNBC. Methods...

10.1186/s13058-020-01374-8 article EN cc-by Breast Cancer Research 2020-11-30

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms

OPENALEX - Publications

Nicole Arellano William L. Heaton Mirielle C. Nauman Abigail E Runnels Jacky Gomez-Villa and 21 more

10.1182/blood.2024026940 article EN Blood 2025-05-22

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

OPENALEX - Publications

Soner Koc Michael W. Lloyd Jeffrey W. Grover Nan Xiao Sara Seepo and 95 more

We created the PDX Network (PDXNet) portal (https://portal.pdxnetwork.org/) to centralize access National Cancer Institute-funded PDXNet consortium resources, facilitate collaboration among researchers and make these data easily available for research. The includes sections analysis results, metrics activities, processing protocols training materials data. Currently, contains model information resources from 334 new models across 33 cancer types. Tissue samples of were deposited in NCI's...

10.1093/narcan/zcac014 article EN cc-by NAR Cancer 2022-04-08

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

OPENALEX - Publications

Katrin P. Guillen Maihi Fujita Andrew Butterfield Sandra D. Scherer Matthew H. Bailey and 37 more

Abstract Model systems that recapitulate the complexity of human tumors and reality variable treatment responses are urgently needed to better understand cancer biology develop more effective therapies. Here we report development characterization a large bank patient-derived xenografts (PDX) matched organoid cultures from represent some greatest unmet needs in breast research treatment. These include endocrine-resistant, treatment-refractory, metastatic cancers and, cases, multiple tumor...

10.1101/2021.02.28.433268 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2021-03-02

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis

OPENALEX - Publications